down arrow

Invivyd, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00534A1025
USD
2.88
0.58 (25.22%)

Dec 22

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.422.95

52 Week

0.353.05
Valuation
Technical
Day's Volume

CASH

2.33 M

Shareholding (Mar 2025)

FII

1.80%

Held by 33 FIIs

DII

70.77%

Held by 20 DIIs

Promoter

15.47%

How big is Invivyd, Inc.?

22-Jun-2025

As of Jun 18, Invivyd, Inc. has a market capitalization of 87.19 million, with net sales of 36.68 million and a net profit of -142.72 million over the last four quarters. Shareholder's funds are 67.54 million, and total assets amount to 129.51 million.

As of Jun 18, Invivyd, Inc. has a market capitalization of 87.19 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 36.68 million, while the sum of net profit for the same period is -142.72 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 67.54 million, and total assets amount to 129.51 million.

Read More

What does Invivyd, Inc. do?

22-Jun-2025

Invivyd, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $11 million and a net loss of $16 million as of March 2025, with a market cap of $87.19 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -263.57%.

Overview: <BR>Invivyd, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 11 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 87.19 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.87 <BR>Return on Equity: -263.57% <BR>Price to Book: 1.61<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Invivyd, Inc. overvalued or undervalued?

20-Sep-2025

As of August 14, 2024, Invivyd, Inc. is rated as risky due to its negative P/E ratio and poor returns on capital and equity, indicating it may be overvalued compared to peers, despite recent short-term gains.

As of 14 August 2024, the valuation grade for Invivyd, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, given its negative P/E ratio and troubling returns on capital and equity, with figures of -2120.73% and -263.57%, respectively. Additionally, the Price to Book Value stands at 2.19, while the EV to Sales ratio is 1.95, both suggesting that the stock may not be justified at its current price.<BR><BR>In comparison to its peers, Invivyd's valuation ratios are significantly weaker, with Poseida Therapeutics, Inc. showing a P/E of -15.2392 and Verastem, Inc. at -4.0339, both indicating a similar risk profile but with less severe metrics. Despite recent strong returns, such as a 115.11% increase over the past month compared to the S&P 500's 2.33%, the long-term outlook remains concerning, particularly with a 3-year return of -67.45% against the S&P 500's 70.41%. This suggests that while short-term gains may be enticing, the overall valuation and financial health of Invivyd, Inc. warrant caution.

Read More

Is Invivyd, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Invivyd, Inc. shows a bullish trend supported by strong short-term indicators, despite mixed longer-term performance, having outperformed the S&P 500 significantly in the past month and year-to-date, but declining over three years.

As of 10 September 2025, the technical trend for Invivyd, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators supporting this view, particularly in the daily moving averages and the weekly MACD, both of which are bullish. The weekly KST also confirms a bullish outlook, while the monthly Bollinger Bands indicate a mildly bearish stance, suggesting some caution. <BR><BR>In terms of performance, Invivyd has significantly outperformed the S&P 500 over the past month with a return of 115.11% compared to the S&P's 2.33%, and year-to-date, it has returned 182.1% versus the S&P's 12.22%. However, the longer-term returns show a decline over three years at -67.45% compared to the S&P's 70.41%. Overall, the current bullish trend is supported by strong short-term indicators, despite mixed signals in longer time frames.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Sales of 420.58%, the company declared Outstanding results in Jun 25

  • The company has declared positive results for the last 2 consecutive quarters
  • NET SALES(Q) At USD 11.79 MM has Grown at 420.58%
  • OPERATING CASH FLOW(Y) Highest at USD -113.11 MM
  • RAW MATERIAL COST(Y) Fallen by -22.8% (YoY)
2

Market Beating Performance

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 226 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.79

stock-summary
Return on Equity

-257.38%

stock-summary
Price to Book

5.29

Revenue and Profits:
Net Sales:
12 Million
(Quarterly Results - Jun 2025)
Net Profit:
-15 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
136.07%
0%
136.07%
6 Months
286.11%
0%
286.11%
1 Year
548.79%
0%
548.79%
2 Years
-25.77%
0%
-25.77%
3 Years
74.55%
0%
74.55%
4 Years
-67.68%
0%
-67.68%
5 Years
0%
0%
0.0%

Invivyd, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
116.18%
EBIT Growth (5y)
3.88%
EBIT to Interest (avg)
-174.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0.45
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
69.68%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.19
EV to EBIT
-0.48
EV to EBITDA
-0.50
EV to Capital Employed
10.27
EV to Sales
1.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-2120.73%
ROE (Latest)
-263.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 18 Schemes (11.96%)

Foreign Institutions

Held by 33 Foreign Institutions (1.8%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 413.04% vs 0.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 68.86% vs 5.98% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.80",
          "val2": "2.30",
          "chgp": "413.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.60",
          "val2": "-48.70",
          "chgp": "70.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.70",
          "val2": "-47.20",
          "chgp": "68.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,277.80%",
          "val2": "-21,752.20%",
          "chgp": "2,047.44%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.45% vs 17.70% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "25.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-173.80",
          "val2": "-205.80",
          "chgp": "15.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-5.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-169.90",
          "val2": "-198.60",
          "chgp": "14.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,968.00%",
          "val2": "0.00%",
          "chgp": "-696.80%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
11.80
2.30
413.04%
Operating Profit (PBDIT) excl Other Income
-14.60
-48.70
70.02%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-14.70
-47.20
68.86%
Operating Profit Margin (Excl OI)
-1,277.80%
-21,752.20%
2,047.44%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 413.04% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 68.86% vs 5.98% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
25.40
0.00
Operating Profit (PBDIT) excl Other Income
-173.80
-205.80
15.55%
Interest
0.00
0.00
Exceptional Items
0.00
-5.00
100.00%
Consolidate Net Profit
-169.90
-198.60
14.45%
Operating Profit Margin (Excl OI)
-6,968.00%
0.00%
-696.80%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 14.45% vs 17.70% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Invivyd, Inc. stock-summary
stock-summary
Invivyd, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."